



Post Authorisation Assessments

Canigen Parvo-C Lyophilisate for Suspension for Injection Vm 01708/4539

•	17 May 2023	Change(s) in the SPC, labelling or package leaflet to various sections. Changes to the product information: Safety warnings.
•	05 January 2023	To replace the tissue culture medium used during finished product formulation (blending) with a basal medium.
•	12 October 2022	To introduce associated non-mixed use of Canigen Parvo-C with Canigen Bb and to update SPC section 4.8 and Package Leaflet section 12 accordingly.
•	28 April 2021	Change in the address of a manufacturer of an active substance.
•	05 November 2020	Change in the name of the marketing authorisation holder from Intervet UK Ltd to MSD Animal Health UK Limited.
•	28 July 2017	To align the pharmaceutical form on the packaging with the SPC. Additionally, the full name has been updated to align with the QRD.
•	10 November 2015	Change in test procedure for the finished product.
•	07 October 2015	Change to compatibility data included with the product. Change to primary packaging. Change to labelling and package leaflet.
•	05 September 2013	Change in name of manufacturer of the finished product
•	04 July 2012	Renewal
•	15 December 2011	To increase the batch size for a portion of the manufacturing procedure.
•	17 March 2009	Variation to change (add) the production site for Canine Parvovirus (CPV).
•	19 January 2009	Variation to the batch safety test on the final product which should be waived.
•	16 June 2008	Corrections/simple text layout changes to SPC and/or product literature.

